Duodenal neuroendocrine tumors are rare neoplasms arising from endocrine cells. Here we present a case of 32-year-old woman with Duodenal neuroendocrine tumors, report the imaging and contrast-enhanced Ultrasound (CEUS) features and review previous literatures of neuroendocrine tumors, which may be valuable for the differential diagnosis of duodenal neoplasms.
LawrenceB, GustafssonBI, ChanA, SvejdaB, KiddM, ModlinIM. The Epidemiology of Gastroenteropancreatic Neuroendocrine Tumors. Endocrinol Metab Clin North Am. 2011;40:1–18.
2.
ModlinIM, KiddM, PfragnerR, EickGN, ChampaneriaMC. The functional characterization of normal and neoplastic human enterochromaffin cells. J Clin Endocrinol Metab2006;91:2340–2348.
3.
BosmanFT. WHO classification of tumours of the digestive system2010.
4.
RindiG, KlöppelG, CouvelardA, KomminothP, KörnerM, LopesJM, et al. TNM staging of midgut and hindgut (neuro) endocrine tumors: a consensus proposal including a grading system. Virchows Arch2007;451:757–762.
5.
ChoMY, KimJM, SohnJH, KimMJ, KimKM, KimWH, et al. Current Trends of the Incidence and Pathological Diagnosis of Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) in Korea -Multicenter Study. Cancer Res Treat2012;44:157–165.
6.
ModlinIM, LyeKD, KiddM. A 5-decade analysis of 13,715 carcinoid tumors. Cancer2003;97:934–959.
7.
SandvikOM, SøreideK, GudlaugssonE, KvaløyJT, SøreideJA. Epidemiology and classification of gastroenteropancreatic neuroendocrine neoplasms using current coding criteria. Br J Surg2016;103:226–232.
8.
HoffmannKM, FurukawaM, JensenRT. Duodenal neuroendocrine tumors: Classification, functional syndromes, diagnosis and medical treatment. Best Pract Res Clin Gastroenterol2005;19:675–697.
9.
BurkeAP, SobinLH, FederspielBH, ShekitkaKM, HelwigEB. Carcinoid tumors of the duodenum. A clinicopathologic study of 99 cases. Arch Pathol Lab Med1990;114:700–704.
10.
AuerTA, FischerT, GarciaSRM, PenzkoferT, JungEM, HammB, et al. Value of contrast-enhanced ultrasound (CEUS) in Focal Liver Lesions (FLL) with inconclusive findings on cross-sectional imaging. Clin Hemorheol Microcirc. 2019
doi:10.3233/CH-190718.
11.
WitzigmannH, LoracherC, GeisslerF, WagnerT, TannapfelA, UhlmannD, etal. Neuroendocrine tumours of the duodenum. Clinical aspects, pathomorphology and therapy. Langenbecks Arch Surg2002;386:525–533.
12.
TiroshA, KebebewE. The utility of 68Ga-DOTATATE positron-emission tomography/computed tomography in the diagnosis, management, follow-up and prognosis of neuroendocrine tumors. Future Oncol. 2018;14(2):111–122.
13.
BodeiL, AmbrosiniV, HerrmannK, ModlinI. Current Concepts in 68 Ga-DOTATATE Imaging of Neuroendocrine Neoplasms: Interpretation, Biodistribution, Dosimetry, and Molecular Strategies. J Nucl Med. 2017;58(11):1718–1726.
14.
VirgoliniI, AmbrosiniV, BomanjiJB, BaumRP, FantiS, GabrielM, et al. Procedure guidelines for PET/CT tumour imaging with 68Ga-DOTA-conjugated peptides: 68Ga-DOTA-TOC, 68Ga-DOTA-NOC, 68Ga-DOTA-TATE. Eur J Nucl Med Mol Imaging. 2010;37(10):2004–10.
15.
SemelkaRC, CustodioCM, CemBalci N, WoosleyJT. Neuroendocrine tumors of the pancreas: spectrum of appearances on MRI. J Magn Reson Imaging2010;11:141–148.
16.
SidhuP S, CantisaniV, DietrichC F, GiljaO H, SaftoiuA, BartelsE, et al. The EFSUMB guidelines and recommendations for the clinical practice of contrast-enhanced ultrasound (CEUS) in nonhepatic applications: update (long version). Ultraschall Med (2018) 39(2),154–180.
17.
LiX, LiJ, LiY, WangH, YangJ, MouS, et al. The role of preoperative ultrasound, contrast-enhanced ultrasound, and 99mTc-MIBI scanning with single-photon emission computed tomography/X-ray computed tomography localization in refractory secondary hyperparathyroidism. Clin Hemorheol Microcirc. 2019;doi:10.3233/CH-190723.
18.
ShroffSR, KushnirVM, WaniSB, GuptaN, JonnalagaddaSS, MuradF, et al. Efficacy of Endoscopic Mucosal Resection for Management of Small Duodenal Neuroendocrine Tumors. Surg Laparosc Endosc Percutan Tech. 2015;25:134–9.
